Hexachlorophene, quercetin, CGP049090 and PKF115-584 were obtained from Sigma-Aldrich (St. Louis, MO). Ionomycin was obtained from Calbiochem (La Jolla, CA). Imatinib was purchased from Novartis International AG (Basel, Switzerland). PNU-74654, ICG-001, PKF118-310, and NSC668036 were synthesized in house. For all experiments, compounds were fleshly prepared by being dissolved in dimethyl sulfoxide (DMSO) or dH2O shortly prior to the experiment. The final concentration of DMSO in each experiment was 0.1%. UE7T-13 cells, human bone-marrow derived mesenchymal stem cell line50 (link), were used. Maintenance and differentiation medium was used DMEM (NICHIREI BIOSCIENCES INC., Tokyo, Japan) containing 10% fetal bovine serum (Nichirei), 100 U/ml penicillin, and 100 μg/ml streptomycin.
Cgp049090
Manufactured by Merck Group
Sourced in France
CGP049090 is a laboratory equipment product. It is designed for use in scientific research and analysis. The core function of this product is to facilitate specific laboratory procedures, but a detailed description cannot be provided while maintaining an unbiased and factual approach.
Automatically generated - may contain errors
Lab products found in correlation
Hexachlorophene, by Merck Group (1 mentions)
Quercetin, by Merck Group (1 mentions)
Imatinib, by Novartis (1 mentions)
Fetal bovine serum (fbs), by Nichirei Biosciences (1 mentions)
Dulbecco modified eagle medium (dmem), by Nichirei Biosciences (1 mentions)
Si β catenin, by GenePharma (1 mentions)
Methyl thiazolyl tetrazolium (mtt), by Merck Group (1 mentions)
Model 680 microplate reader, by Bio-Rad (1 mentions)
Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions)
Sw480, by Corning (1 mentions)
Leibovitz s l 15 medium, by Corning (1 mentions)
Caco 2, by R&D Systems (1 mentions)
Recombinant human wnt3a, by R&D Systems (1 mentions)
Caco 2, by Corning (1 mentions)
Sw480, by Merck Group (1 mentions)
Sw480, by American Type Culture Collection (1 mentions)
Caco 2, by American Type Culture Collection (1 mentions)
3 protocols using cgp049090
1
Mesenchymal Stem Cell Differentiation Assay
2
Evaluating miR-506 and AEG-1 Modulation on MG63 Cell Viability
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For cell viability assays, MG63 cells were transfected with miR-506 mimic or si-AEG-1. Following transfection for 48 h, MG63 cells were seeded in a 96-well plate at a density of 4×103 cells per well. After incubation for 24, 48, 72 and 96 h at 37°C in a humidified atmosphere containing 5% CO2, 10 µl MTT [5 mg/ml in phosphate-buffered saline (PBS); Sigma-Aldrich] was added to each well and the plates were incubated for a further 4 h. After removal of the medium, each cell was treated with 150 µl dimethyl sulfoxide to dissolve the formazan crystals. Optical density values were determined using a microplate reader (Model 680 Microplate Reader; Bio-Rad Laboratories, Inc.) at a wavelength of 490 nm.
MG63 cells transfected with si-β-catenin (sense, 5′-CAGUUGUGGUUAAGCUCUUdTdT-3′ and antisense, 3′-dTdTGUCAACACCAAUUCGAGAA-5′; Genepharma, Co., Ltd) or treated with 0, 5 and 10 µM CGP049090 (Sigma-Aldrich) were seeded in a 96-well plate and incubated for 48 h at 37°C in a humidified atmosphere containing 5% CO2. The subsequent MTT was as aforementioned.
MG63 cells transfected with si-β-catenin (sense, 5′-CAGUUGUGGUUAAGCUCUUdTdT-3′ and antisense, 3′-dTdTGUCAACACCAAUUCGAGAA-5′; Genepharma, Co., Ltd) or treated with 0, 5 and 10 µM CGP049090 (Sigma-Aldrich) were seeded in a 96-well plate and incubated for 48 h at 37°C in a humidified atmosphere containing 5% CO2. The subsequent MTT was as aforementioned.
3
CRC Cell Lines Wnt3a and CGP049090 Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human CRC cell lines, SW480 and Caco-2, were purchased from the American Type Culture Collection (Manassas, VA, USA). SW480 was cultured in Leibovitz’s L-15 Medium (Corning Cellgro®, Manassas, VA, USA) and Caco-2 in MEM Medium (Corning Cellgro®). All culture media were supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Cells were maintained at 37 °C/5% CO2 in a humidified incubator. Recombinant human Wnt3a (R&D System, Minneapolis, MN, USA) was used at a concentration of 100 ng/mL for treating Caco-2/E12 and Caco-2/E47 cells to activate β-catenin. CGP049090 (Sigma-Aldrich, Lyon, France), a small-molecule inhibitor of Wnt/β-catenin, was diluted in 10 μM for treating SW480/shE2A cells.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!